Changes in Endogenous Oxytocin Levels and the Effects of Exogenous Oxytocin Administration on Body Weight Changes and Food Intake in Polycystic Ovary Syndrome Model Rats

Polycystic ovary syndrome (PCOS) is frequently seen in females of reproductive age and is associated with metabolic disorders that are exacerbated by obesity. Although body weight reduction programs via diet and lifestyle changes are recommended for modifying reproductive and metabolic phenotypes, t...

Full description

Saved in:
Bibliographic Details
Published in:International journal of molecular sciences 2022-07, Vol.23 (15), p.8207
Main Authors: Yamamoto, Shota, Noguchi, Hiroki, Takeda, Asuka, Arakaki, Ryosuke, Uchishiba, Maimi, Imaizumi, Junki, Minato, Saki, Kamada, Shuhei, Kagawa, Tomohiro, Yoshida, Atsuko, Kawakita, Takako, Yamamoto, Yuri, Yoshida, Kanako, Kon, Masafumi, Shinohara, Nobuo, Iwasa, Takeshi
Format: Article
Language:English
Subjects:
Body fat
Body weight
Body weight gain
Dihydrotestosterone
Food
Food intake
Gene expression
Hypothalamus
Lipolysis
Metabolic disorders
Neuropeptides
Obesity
Ovaries
Oxytocin
Phenotypes
Polycystic ovary syndrome
Uterus
Weight reduction
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Polycystic ovary syndrome (PCOS) is frequently seen in females of reproductive age and is associated with metabolic disorders that are exacerbated by obesity. Although body weight reduction programs via diet and lifestyle changes are recommended for modifying reproductive and metabolic phenotypes, the drop-out rate is high. Thus, an efficacious, safe, and continuable treatment method is needed. Recent studies have shown that oxytocin (OT) reduces body weight gain and food intake, and promotes lipolysis in some mammals, including humans (especially obese individuals), without any adverse effects. In the present study, we evaluated the changes in endogenous OT levels, and the effects of acute and chronic OT administration on body weight changes, food intake, and fat mass using novel dihydrotestosterone-induced PCOS model rats. We found that the serum OT level was lower in PCOS model rats than in control rats, whereas the hypothalamic OT mRNA expression level did not differ between them. Acute intraperitoneal administration of OT during the dark phase reduced the body weight gain and food intake in PCOS model rats, but these effects were not observed in control rats. In contrast, chronic administration of OT decreased the food intake in both the PCOS model rats and control rats. These findings indicate that OT may be a candidate medicine that is efficacious, safe, and continuable for treating obese PCOS patients.
ISSN:1422-0067
1661-6596
1422-0067
DOI:10.3390/ijms23158207